Clinical trials: Coronary Ischemia
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA
This study will evaluate the level of agreement between noninvasive CCTA (coronary computed tomography angiography)-based quantification and characterization of coronary atherosclerosis and invasive IVUS (intravascular…
- Trial name
- REVEALPLAQUE (NCT05138289)
- Testing
- Total Plaque Volume
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- HeartFlow, Inc.
Coronary Artery Disease, Ischemic Heart Disease
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
- Trial name
- ECLIPSE (NCT03108456)
- Testing
- Orbital Atherectomy, Balloon
- Where
- 104 sites in United States
- Volunteers
- 2,005 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
OPTIMIZE PCI: Multicenter Randomized Trial of OCT Compared to IVUS and Angiography to Guide Coronary Stent Implantation
The objective of this clinical investigation is to demonstrate the safety and efficacy of an OCT guided strategy for stent implantation
- Trial name
- ILUMIEN III (NCT02471586)
- Testing
- Coronary PCI guided by IVUS, Coronary PCI guided by OCT, Coronary PCI guided by Angiography
- Where
- 29 sites in United States, Belgium and 6 more
- Volunteers
- 450 people
- Sponsor
- Abbott Medical Devices
Coronary Heart Disease
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
The purpose of this study is to learn if CS-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery…
- Trial name
- NCT00185042
- Testing
- Pactimibe, CS-505
- Where
- 46 sites in United States
- Volunteers
- 534 people
- Sponsor
- Daiichi Sankyo
Mixed Dyslipidemia, Coronary Heart Disease
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with multiple abnormal lipid levels in the…
- Conditions
- Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
- Trial name
- NCT00300469
- Testing
- ABT-335, Atorvastatin
- Where
- United States
- Volunteers
- 613 people
- Sponsor
- Abbott
Coronary Artery Disease, Coronary Artery Stenosis
First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
BIOSOLVE-II is a prospective, international, multicenter, First in Man study. The purpose of this study is to assess the safety and clinical performance of the drug eluting absorbable metal scaffold (DREAMS 2nd Generation).
- Trial name
- BIOSOLVE-II (NCT01960504)
- Testing
- Percutaneous Coronary Intervention (DREAMS) stenting
- Where
- 13 sites in Belgium, Brazil and 6 more
- Volunteers
- 123 people
- Sponsor
- Biotronik AG
Coronary Artery Disease
Hydroxyapatite Active Pro Healing Clinical Trial Program
The purpose of this first feasibility study is to evaluate the performance of Vesta™ \& VestaCOR™ (Hydroxy-Apetite coated GenX) stent in de novo native coronary artery lesions.
- Trial name
- HApFIM (NCT00474084)
- Testing
- Intravascular Coronary Stent
- Volunteers
- 70 people
- Sponsor
- BioSync Scientific Pvt. Ltd.
Coronary Artery Disease
Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement
This study will assess the differences between Fractional Flow Reserve (FFR) measurements made by the Navvus catheter and a commercially available pressure guidewire in up to 240 subjects where FFR is clinically indicated.
- Trial name
- ACIST-FFR (NCT02577484)
- Testing
- RXi System, Pressure Wire
- Where
- 12 sites in United States
- Volunteers
- 240 people
- Sponsor
- Acist Medical Systems
Coronary Artery Disease
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please in Korean Patients With Coronary In-stent Restenosis
The purpose of this study is to evaluate the safety and efficacy of Paclitaxel-coated balloon (Genoss® DCB) by demonstrating non-inferiority to in-segment late lumen loss at 6 months after the procedure in patients with in-stent…
- Trial name
- NCT04405063
- Testing
- Paclitaxel Coated PTCA Balloon Catheter
- Volunteers
- 82 people
- Sponsor
- Genoss Co., Ltd.
Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
The 3D Stent Study
The goal of this observational study is to assess the diagnostic performance of 3D Stent to detect stent under-expansion in patients undergoing percutaneous coronary intervention.
- Trial name
- NCT06898021
- Testing
- 3DStent
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 200 people
- Sponsor
- CoreAalst BV
Coronary Heart Disease
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
This double-blind, randomized, placebo-controlled, multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome (ACS).
- Trial name
- NCT01323153
- Testing
- dalcetrapib
- Where
- 33 sites in United States, Czechia and 2 more
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
Coronary Disease
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
The primary focus of this study is to explore the safety of a range of doses of rNAPc2 in subjects who are managed in hospitals that most typically practice an early invasive strategy (catheterization during the index admission).
- Trial name
- NCT00116012
- Testing
- rNAPc2
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- ARCA Biopharma, Inc.
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease
This trial is to compare PB127 echocardiography to other heart imaging studies.
- Trial name
- NCT00595244
- Testing
- PB127 for injectable suspension
- Where
- 15 sites in United States
- Volunteers
- 456 people
- Sponsor
- Point Biomedical
Hypertension, Coronary Arteriosclerosis
Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
Effects of AT1 receptor antagonist telmisartan on the primary endpoint inflammatory parameters in patients with coronary artery disease (CAD). Secondary endpoints are alterations in clinical course and blood pressure
- Trial name
- NCT00274144
- Testing
- telmisartan 40 mg
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Coronary Disease, Diabetes Mellitus
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in…
- Trial name
- ILLUMINATE (NCT00134264)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 221 sites in United States, Australia and 5 more
- Volunteers
- 15,067 people
- Sponsor
- Pfizer
Coronary Heart Disease
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD…
- Trial name
- NCT06031844
- Testing
- DFV890
- Where
- 7 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion
The MARKOV study is an investigator-sponsored single arm, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patients with coronary…
- Trial name
- MARKOV (NCT03851263)
- Testing
- Evolocumab
- Sponsor
- ECRI bv
Coronary Artery Disease (CAD)
Coroflex ISAR 2000 Extended Registry (ISAR2000 Extended)
Postmarket surveillance in terms of the safety and efficacy of Sirolimus-eluting Coroflex ISAR Stent for the treatment of "real world" patients with de-novo and restenotic lesions after stand-alone angioplasty in coronary…
- Trial name
- NCT02905214
- Testing
- stenting with the Coroflex ISAR sirolimus-eluting stent
- Where
- 3 sites in Germany, Malaysia and 1 more
- Volunteers
- 4,369 people
- Sponsor
- B. Braun Melsungen AG
Hypercholesterolemia, Coronary Heart Disease
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, Cerebrovascular Accident
- Trial name
- HEROS (NCT00660764)
- Testing
- Rosuvastatin
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.